Evidence map›Paper›PMID 36129760›Full record

ArticleJCI insight2022

Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis.

Yusuke Isshiki, Motohiko Oshima, Naoya Mimura, Kensuke Kayamori, Yurie Miyamoto-Nagai, Masahide Seki, Yaeko Nakajima-Takagi, Takashi Kanamori, Eisuke Iwamoto, Tomoya Muto and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Yusuke IsshikiDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Motohiko OshimaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Naoya MimuraDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Kensuke KayamoriDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Yurie Miyamoto-NagaiDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Masahide SekiLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yaeko Nakajima-TakagiDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takashi KanamoriDepartment of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Eisuke IwamotoDepartment of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Tomoya MutoDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Shokichi TsukamotoDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Yusuke TakedaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Chikako OhwadaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Sonoko MisawaDepartment of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.
Jun-Ichiro IkedaDepartment of Pathology, Chiba University Hospital, Chiba, Japan.
Masashi SanadaDepartment of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Satoshi KuwabaraDepartment of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.
Yutaka SuzukiLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Chiaki NakasekoDepartment of Hematology, International University of Health and Welfare, Chiba, Japan.
Atsushi IwamaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Chiba University Hospital · JPThe University of Tokyo · JPNational Hospital Organization · JPChiba University · JPInternational University of Health and Welfare · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

POEMS syndrome is a rare monoclonal plasma cell disorder, with unique symptoms distinct from those of other plasma cell neoplasms, including high serum VEGF levels. Because the prospective isolation of POEMS clones has not yet been successful, their real nature remains unclear. Herein, we performed single-cell RNA-Seq of BM plasma cells from patients with POEMS syndrome and identified POEMS clones that had Ig λ light chain (IGL) sequences (IGLV1-36, -40, -44, and -47) with amino acid changes specific to POEMS syndrome. The proportions of POEMS clones in plasma cells were markedly smaller than in patients with multiple myeloma (MM) and patients with monoclonal gammopathy of undetermined significance (MGUS). Single-cell transcriptomes revealed that POEMS clones were CD19+, CD138+, and MHC class IIlo, which allowed for their prospective isolation. POEMS clones expressed significantly lower levels of c-MYC and CCND1 than MM clones, accounting for their small size. VEGF mRNA was not upregulated in POEMS clones, directly indicating that VEGF is not produced by POEMS clones. These results reveal unique features of POEMS clones and enhance our understanding of the pathogenesis of POEMS syndrome.

Indexed as

Multiple MyelomaPOEMS SyndromeAmino AcidsClone CellsHumansImmunoglobulin lambda-ChainsImmunoglobulin Light ChainsPlasma CellsSingle-Cell AnalysisVascular Endothelial Growth Factor AAmino AcidsImmunoglobulin lambda-ChainsImmunoglobulin Light ChainsVascular Endothelial Growth Factor ABone marrowClonal selectionHematologyLymphomas

Identifiers

PMID36129760
PMCPMC9714781
OpenAlexW4296709151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.